Biotechnology deals are off to a strong start in 2018, thanks to the Biotech Showcase 2018 held every year alongside the J.P. Morgan Healthcare Conference. In the first two weeks, 16 transactions were made public. This year, the Showcase registration desk was just getting into full swing on Sunday, January 7, when Celgene Corp. (NASDAQ: CELG) […]
The Medical Device sector has been humming. Granted, it comprises a huge range of things, from hip and knee joints to cardiovascular devices. Since 2016, 176 deals have been announced, and $102 billion has been committed based on 73 disclosed prices. Among the 176 deals, 14 target companies specialize in cardiovascular devices, 14 specialize in orthopedic […]
Biotechnology deal activity has climbed steadily over the past five quarters. The sector reached 62 transactions in Q1:17, an increase of 13% over the previous quarter and up 94% year-over-year. The total is 31% of the 203 deals announced in the previous 12 months. M&A in this sector will remain active for years to come, […]
Deals for medical device companies have slowed considerably since 2016. The sector seems to be gaining new life as the second quarter of 2017 begins.
There’s been a sharp drop in Pharmaceutical deals in the first quarter of 2017, compared with a year ago. What’s up with that?
Perrigo finally sold its royalty interest in Tysabri, a multiple sclerosis drug that it acquired as part of Elan Corporation back in 2013. Royalty Pharma, the hostile bidder for Elan back then, paid $2.2 billion for Tysabri royalties.
Healthcare deal volume got off to a good start in 2017 as January’s total reached 156 transactions.
Johnson & Johnson swallowed hard and upped its bid for Swiss biotech Actelion, winning the deal with a $30.2 billion bid.
Medical Devices is finishing the year on a high note. In fact, as of December 29, 2016, deal volume reached 113 transactions, equal to 2015’s total. Deal value topped off at $61.3 billion, a 111% increase from last year’s total of $29.1 billion.
Johnson & Johnson (NYSE: JNJ) announced the restructuring of its medical devices business on January 19, 2016. Its 8K filing noted pre-tax restructuring charges of $2.0 billion to $2.4 billion, expected to be incurred this year, as well as a Q4:15 charge of approximately $600 million. About 4% to 6% of the division’s global workforce will get […]